NK1R-targeted radiolabeled small molecules

NK1R-targeted radiolabeled small molecules are a class of theranostic agents designed for the precision imaging and targeted radiotherapy of neuroblastoma and other neural tumors. Developed by researchers at Uppsala University and the University of Texas Southwestern Medical Center, these small molecules are designed to selectively bind to the neurokinin-1 receptor (NK1R, also known as tachykinin receptor 1 or TACR1), which is highly overexpressed in neuroblastoma, glioblastoma, childhood leukemia, and osteosarcoma. By incorporating radiohalogens or other isotopes (such as iodine or lutetium), these agents can be utilized for both diagnostic imaging and targeted radionuclide therapy, offering a personalized theranostic approach to inhibit tumor growth, angiogenesis, and metastasis.

Other names

NK1R-targeted radiopharmaceuticalsNK-1R-targeted radiopharmaceuticalsNK 1R-targeted radiopharmaceuticalsNeuroblastoma TheranosticsTACR1-targeted radiolabeled small moleculesTACR-1-targeted radiolabeled small moleculesTACR 1-targeted radiolabeled small molecules